This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: E70.8 (other disorders of aromatic amino acid metabolism) | Special Copayment Reduction: V117 (rare disease, 10% copayment for 5 years after registration) |
| B. Synonyms | Disorders of histidine metabolism (histidinemia, Histidinemia, HAL deficiency), disorders of tryptophan metabolism (Hartnup disease, carcinoid syndrome-like type, indicanuria), urocanase deficiency, formiminoglutamic aciduria |
| C. Adult onset | Possibility of first onset in adulthood yes (varies by disease) — histidinemia is mostly benign and asymptomatic and found incidentally in adulthood; Hartnup disease presents intermittently, so first diagnosis in adulthood is also possible; carcinoid-related tryptophan metabolic abnormalities cause symptoms from middle age onward. |
| 1. History | 1961 Ghadimi first reports histidinemia → 1956 Baron describes Hartnup disease → 2000s SLC6A19 (Hartnup) and HAL genes identified → now reclassified as benign metabolic abnormalities. |
| 2. Causes | Histidinemia: deficiency of the HAL (histidase) enzyme (HAL gene). Hartnup disease: defect of the intestinal and renal neutral amino acid transporter (SLC6A19 gene). Tryptophan metabolic abnormalities: various enzyme and transporter defects. |
| 3. Genetics | Histidinemia: HAL gene (12q22-q23.1), autosomal recessive. Hartnup disease: SLC6A19 (5p15.33), autosomal recessive. Population frequency: Hartnup disease ~1/30,000, histidinemia ~1/8,000-12,000. |
| 4. General epidemiology | Histidinemia: about 1/8,000–12,000 on newborn screening. Hartnup disease: ~1/30,000. Both equal in males and females. Korea: few diagnosed through newborn screening; low clinical significance. |
| 5. Pathophysiology | Histidinemia: HAL deficiency → conversion of histidine to urocanic acid blocked → accumulation of histidine in blood and urine. Hartnup disease: malabsorption of neutral AA in the intestine and kidney → tryptophan deficiency → niacin (NAD) deficiency → pellagra-like symptoms. |
| 6. Symptoms | Histidinemia: mostly asymptomatic; some speech delay (causality uncertain). Hartnup disease: intermittent skin rash (photosensitive, pellagra-like), neurological symptoms (ataxia), psychiatric symptoms, polyuria. |
| 7. Signs | Histidinemia: increased blood histidine (>500 μmol/L), increased urine histidine and imidazole metabolites. Hartnup disease: intermittent skin lesions (scaly erythema), neurological abnormalities (ataxia, tremor), aminoaciduria (neutral amino acids overall). |
| 8. Screening | Histidinemia: newborn screening in some countries (blood histidine measurement); eligible for Special Copayment Reduction in Korea, but low clinical value of screening. Hartnup disease: few countries include it in newborn screening; urine amino acid analysis when symptomatic. |
| 9. Diagnosis | Plasma amino acid analysis (elevated histidine), urine organic acid and amino acid analysis, enzyme activity measurement, molecular genetic testing (HAL, SLC6A19). Hartnup disease: confirmation of urinary neutral aminoaciduria. |
| 10. Treatment | Histidinemia: mostly no treatment needed. Hartnup disease: adequate protein intake + nicotinamide (niacinamide) supplementation (50–300 mg/day), UV protection, skin moisturizing. Mainly symptomatic treatment. |
| 11. Prognosis | Histidinemia: mostly normal prognosis. Hartnup disease: skin and neurological symptoms resolve with nicotinamide supplementation; normal life possible. Overall life expectancy normal. |
| 12. Prevention | Genetic counseling. Hartnup disease: high-protein diet, adequate niacin intake, photoprotection. Histidinemia: no specific prevention needed. Early identification through newborn screening. |
| 13. References | Ghadimi H et al. Histidinemia. N Engl J Med. 1961;265:221-224 … and 9 other papers |
Disorders of aromatic amino acid metabolism (E70.8) are, like phenylketonuria (E70.0) and alkaptonuria (E70.2), a group of rare metabolic diseases caused by deficiency of a specific enzyme or abnormal transport in aromatic amino acid metabolism, and are classified in ICD-10 under E70.8 (other disorders of aromatic amino acid metabolism). This category includes several diseases of varying clinical significance, the representative ones being disorders of histidine metabolism (histidinemia) and disorders of tryptophan metabolism (including Hartnup disease).
History of histidinemia: histidinemia became known in 1961 when the American pediatrician Horace Ghadimi and colleagues first reported pediatric patients with markedly elevated blood histidine concentrations. Early reports claimed an association with speech disorders and intellectual disability, and as a result histidinemia was included in the newborn screening panels of some countries in the 1960s–70s. However, large follow-up studies over the following decades confirmed that most individuals with histidinemia are neurodevelopmentally normal, and through the 1980s–90s histidinemia underwent reclassification as a benign metabolic variant. The HAL (histidase/histidine ammonia-lyase) gene is located at 12q22-q23.1 and was fully cloned and characterized in the early 2000s.
History of Hartnup disease: in 1956, Baron et al. in London, UK, reported four siblings from a family with the surname Hartnup who showed intermittent skin rash (photosensitive, pellagra-like), ataxia, and psychiatric symptoms, and named it 'Hartnup disease'. The biochemical feature was neutral aminoaciduria, with massive excretion of neutral amino acids (including tryptophan) in the urine. Subsequent studies showed that the clinical symptoms of Hartnup disease result mainly from niacin (nicotinic acid) deficiency due to insufficient tryptophan absorption, that is, pellagra. The causative gene SLC6A19 was identified independently in 2004 by Kleta et al. and Seow et al., and it is located at 5p15.33 and encodes B0AT1, a sodium-dependent neutral amino acid transporter.
In addition, formiminoglutamic aciduria (FIGLU-uria) is caused by deficiency of formiminotransferase (FTCD, glutamate formiminotransferase-cyclodeaminase) in the histidine degradation pathway and was first described in 1959 by Aiken et al. Indicanuria is a condition in which indole compounds increase owing to abnormal degradation of tryptophan by intestinal bacteria, and it often appears as a secondary phenomenon of small intestinal malabsorption or Hartnup disease rather than as an independent genetic disease. In carcinoid tumors, tryptophan is excessively diverted to the serotonin production pathway, causing a secondary tryptophan metabolic abnormality that leads to niacin deficiency.
The causes of each disease belonging to disorders of aromatic amino acid metabolism (E70.8) are distinguished as follows.
Disorders of histidine metabolism (histidinemia): caused by deficiency of histidase, the histidine-degrading enzyme, due to mutations in the HAL (histidine ammonia-lyase) gene. Histidase is expressed mainly in the liver and skin and catalyzes the conversion of histidine to urocanic acid. When this enzyme is deficient, blood histidine rises to 5–15 times normal or more, and abnormal metabolites such as imidazoleacetic acid, imidazolelactic acid, and imidazolepyruvic acid are excreted in the urine. Histidinemia is not a complete metabolic block, because histidine is partly degraded by an alternative pathway through another histidine-degrading enzyme (histidine–pyruvate aminotransferase) whose cofactor is fermented pyridoxal phosphate (PLP, vitamin B6).
Disorder of tryptophan metabolism — Hartnup disease: mutations in the SLC6A19 gene cause loss of function of the transporter B0AT1, which is responsible for sodium-dependent absorption of neutral amino acids (especially tryptophan, alanine, valine, isoleucine, leucine, histidine, serine, threonine, glycine, glutamine, and asparagine) in the epithelial cells of the small intestine and renal proximal tubule. As a result, neutral amino acids including tryptophan are not absorbed in the gut and pass to the colon, where they are degraded by intestinal bacteria into indole compounds and absorbed, and in the kidney, poor reabsorption of filtered amino acids causes aminoaciduria. Reduced tryptophan supply decreases the availability of tryptophan, which is essential for the synthesis of serotonin, melatonin, and niacin (an NAD precursor), and niacin deficiency in particular is the key cause of the pellagra-like symptoms.
Other disorders of tryptophan metabolism: there are kynurenine pathway enzyme deficiencies such as kynureninuria due to kynurenine hydroxylase (KMO) deficiency, xanthurenic aciduria (pyridoxine-dependent kynureninase deficiency), and hydroxykynureninuria. These are divided into B6-responsive and non-responsive forms. Formiminoglutamic aciduria (FIGLU-uria) is the accumulation of formiminoglutamic acid due to formiminotransferase (FTCD) deficiency in the histidine degradation pathway (histidine → urocanic acid → imidazolonepropionic acid → formiminoglutamic acid → glutamic acid), and is also a disorder of a folate cofactor-dependent reaction.
Histidinemia: the HAL gene is located on the long arm of chromosome 12 (12q22-q23.1) and encodes histidase (HAL, EC 4.3.1.3), which belongs to the aromatic amino acid transferase superfamily. Various pathogenic variants, including point mutations, deletions, and splicing variants, have been reported in this gene. The mode of inheritance is autosomal recessive (AR), and heterozygous carriers are asymptomatic. The genetic diagnostic yield for histidinemia by molecular genetic testing is relatively high, but because its clinical significance is low, comprehensive genetic testing is not routinely performed.
Hartnup disease: the SLC6A19 gene is located on the short arm of chromosome 5 (5p15.33) and encodes B0AT1, a sodium-dependent neutral amino acid transporter and member of solute carrier family 6 (SLC6). The mode of inheritance is autosomal recessive (AR). Most reported mutations are missense and nonsense variants, and complete loss-of-function variants tend to be associated with a more severe phenotype. However, even with the same homozygous mutation, interindividual variation in clinical phenotype is large. This is explained by the large influence of environmental modifying factors such as dietary protein intake, intestinal bacterial composition, and pyridoxine and niacin intake status.
Prevalence: Hartnup disease is estimated at about 1/30,000 worldwide, and histidinemia is relatively more common at about 1/8,000–1/12,000. Both diseases occur with equal frequency in males and females. Histidinemia was formerly included in newborn screening in some countries (Japan, some US states), but after the consensus that it is a benign metabolic abnormality, it was removed from most screening panels. Dozens of pathogenic variants are registered in the SLC6A19 variant database, and studies of the specific variant spectrum in East Asian populations are under way.
The epidemiology of the individual diseases included in disorders of aromatic amino acid metabolism (E70.8) differs for each. Based on newborn screening results, histidinemia is a relatively common inherited metabolic disease occurring at a frequency of about 1/8,000–1/12,000 births. In the past, it was included in Japan's national newborn screening program and a considerable number of patients were identified, but it was removed from screening after the 1990s once its clinical harmlessness was confirmed. It occurs in all ethnic groups worldwide and equally in males and females.
Hartnup disease is estimated at a frequency of about 1/30,000 births and is not uncommon worldwide, but because clinical symptoms are intermittent and mild, it often goes undiagnosed. In settings with adequate dietary protein intake it is almost asymptomatic, and clinical symptoms tend to appear in situations of malnutrition. Accordingly, there are reports that symptoms appear relatively more often in developing countries. Other disorders of tryptophan and histidine metabolism (kynureninuria, formiminoglutamic aciduria, indicanuria, etc.) are even rarer diseases, with only dozens to hundreds of cases each reported, making accurate prevalence estimates difficult.
In Korea, these diseases are included in V117 Special Copayment Reduction, but the number of patients registered in Korea is extremely small, and clinically problematic cases are even rarer. Histidine is measured in the newborn tandem mass spectrometry (TMS) screening panel, but because the clinical significance of histidinemia is low, debate continues about the practical benefit of screening. Symptomatic Hartnup disease patients in Korea are managed within a multidisciplinary care system including internal medicine, neurology, and dermatology, and symptoms can be controlled with nicotinamide supplementation.
Pathogenesis of disorders of histidine metabolism (histidinemia): histidase (HAL, EC 4.3.1.3) is the first enzyme that breaks down histidine into urocanic acid and ammonia. This enzyme is expressed mainly in the liver and skin and uses pyridoxal phosphate (PLP) as a cofactor. When enzyme function is lost due to HAL gene mutations, histidine cannot be converted to urocanic acid and accumulates in the blood, causing histidinemia. Accumulated histidine is partly converted through an alternative pathway (histidine transaminase) to imidazolepyruvic acid, imidazolelactic acid, and imidazoleacetic acid, which are detected in the urine. Because urocanic acid plays an immunomodulatory role in the skin through ultraviolet (UV) absorption, changes in skin immune function are theoretically possible, but the clinical significance is unclear. The reason neurodevelopmental disorders do not appear in histidinemia is explained by histidine concentrations not reaching neurotoxic levels even when high, and by maintenance of alternative metabolic pathways.
Pathogenesis of Hartnup disease: the SLC6A19 transporter (B0AT1) is located in the apical membrane of small intestinal epithelial cells and renal proximal tubular epithelial cells and transports electrically neutral amino acids (neutral amino acids, especially nonpolar aliphatic and aromatic amino acids) from the lumen into the cell in a sodium-dependent manner. When this transporter loses function due to SLC6A19 mutation, (1) absorption of neutral amino acids such as tryptophan and alanine in the small intestine decreases markedly, and (2) reabsorption of already filtered amino acids in the renal proximal tubule is blocked, causing neutral aminoaciduria. When unabsorbed tryptophan is degraded by bacteria in the colon into indole, skatole, tryptamine, and the like and absorbed, indicanuria appears. Reduced tryptophan availability → reduced synthesis of niacin (an NAD precursor) → impaired cellular energy metabolism and DNA repair → photosensitive skin rash (pellagra-like), neurological symptoms (cerebellar ataxia, personality change), and so on.
Disorders of histidine metabolism (histidinemia): clinically mostly asymptomatic, and the current scientific consensus regards histidinemia as a benign metabolic abnormality. Early reports in the 1960s–70s raised associations with speech disorders, learning disabilities, and intellectual disability, but subsequent long-term follow-up studies repeatedly confirmed that the language and cognitive development of individuals with histidinemia does not differ from normal controls. Therefore, unnecessary treatment or anxiety due to the diagnosis of histidinemia itself should be minimized. Rarely, a peculiar odor of the urine due to urinary excretion of histidine metabolites has been reported, but it is not classified as a clinically meaningful symptom.
Hartnup disease (disorder of tryptophan metabolism): clinical symptoms appear intermittently, and triggers include insufficient dietary protein intake, sun exposure, fever, psychological stress, and diarrhea. The main symptoms fall into three categories. (1) Skin symptoms: a photosensitive rash, with pellagra-like erythematous scaly dermatitis on exposed areas (face, neck, arms). (2) Neurological symptoms: intermittent cerebellar ataxia (gait instability, limb incoordination), headache, dizziness, tremor. (3) Psychiatric symptoms: anxiety, mood instability, and rarely hallucinations and delusions. Diagnosis is easy when the typical triad of these three symptoms appears together, but it is also common for individual symptoms to appear alone. Symptom severity is closely related to nutritional status, and in settings with adequate protein and niacin intake patients can remain almost asymptomatic.
Other disorders of aromatic amino acid metabolism: in formiminoglutamic aciduria (FIGLU-uria), mild cognitive impairment, intellectual disability, and the like associated with abnormal folate metabolism have been reported in some cases. In xanthurenic aciduria, neurological symptoms responsive to vitamin B6 supplementation may appear. There are studies suggesting that kynurenine pathway abnormalities affect serotonin and niacin synthesis and may be associated with a wide range of neuropsychiatric symptoms, but a direct causal relationship has not yet been clearly established.
Test findings in histidinemia: plasma amino acid analysis shows a marked elevation of histidine (from a normal 70–200 μmol/L to 500–3,000 μmol/L or more). Urine amino acid analysis shows increased histidine excretion, and organic acid analysis shows increased imidazolepyruvic acid, imidazolelactic acid, and imidazoleacetic acid. Physical examination findings are mostly normal, with no skin, neurological, or endocrine abnormalities. A marked decrease in HAL activity on enzyme activity measurement is used for confirmation.
Test findings in Hartnup disease: (1) Urine amino acid analysis: a marked increase in excretion of neutral amino acids overall (tryptophan, alanine, valine, isoleucine, leucine, histidine, serine, threonine, glycine, glutamine, asparagine) is the biochemical definition of Hartnup disease. Excretion of proline, hydroxyproline, and acidic and basic amino acids is normal, distinguishing it from Fanconi syndrome, a generalized aminoaciduria. (2) Plasma amino acids: normal or slightly decreased. An isolated decrease in blood tryptophan is sometimes observed. (3) Urine indole test: indicanuria is confirmed by increased indican (indoxyl sulfate) in the urine. (4) Skin findings: erythematous scaly rash on exposed areas; it may be clinically difficult to distinguish from pellagra, the skin lesion of niacin deficiency. (5) Neurological examination: when cerebellar ataxia is present, incoordination is observed on gait testing, finger-to-nose testing, and the like; brain MRI is usually normal, but cerebellar atrophy has been reported in some.
Histidinemia: formerly included in newborn screening in some countries (Japan, some Canadian provinces, some US states), but it has now been removed from screening panels in most countries because of its low clinical significance. In Korea's national newborn tandem mass screening, measurement of blood histidine is technically possible but is not included as an official screening item. Even if histidinemia is found incidentally, current guidelines often regard it as a benign metabolic abnormality and recommend observation only, without therapeutic intervention. However, it is included in Special Copayment Reduction (V117), so confirmed cases can receive medical cost support.
Hartnup disease: generally not included in newborn screening panels. Urinary neutral aminoaciduria, the main biochemical feature of Hartnup disease, is not directly detected by routine newborn screening methods. When there is clinical suspicion (children or adults with intermittent skin rash, ataxia, and psychiatric symptoms), diagnostic clues are obtained through urine amino acid analysis (ion-exchange chromatography). When nutritional status is good, there may be no clinical symptoms, so the disease may go undiagnosed without abnormal findings on urine amino acid analysis. When there is a family history, preemptive confirmation through molecular genetic testing (SLC6A19) is possible.
Diagnosis of histidinemia: (1) Plasma amino acid analysis: measurement of blood histidine concentration by ion-exchange chromatography or tandem mass spectrometry. The confirmatory criterion is blood histidine >500 μmol/L. (2) Urine organic acid and amino acid analysis: confirmation of increased imidazole metabolites. (3) Enzyme activity testing: measurement of HAL activity in skin fibroblasts or liver biopsy. (4) Molecular genetic testing: confirmation of pathogenic variants by NGS testing of the HAL gene.
Diagnosis of Hartnup disease: (1) Urine amino acid analysis (ion-exchange chromatography): massive excretion of neutral amino acids overall is the key diagnostic finding, with particularly marked increases in excretion of tryptophan, alanine, glutamine, and asparagine. Without this finding, Hartnup disease cannot be diagnosed. (2) Quantitative urine indole test: increased indican (indoxyl sulfate). (3) Plasma amino acids: mostly normal, but tryptophan is sometimes slightly decreased. (4) Molecular genetic testing: confirmed by SLC6A19 gene analysis; confirmed when pathogenic variants are found on both alleles. (5) Differential diagnosis: needs to be distinguished from aminoaciduria due to other causes (Fanconi syndrome — generalized aminoaciduria, with acidic and basic amino acids also increased), vitamin-deficiency pellagra (dietary niacin deficiency alone), and cerebellar ataxia (other causes of ataxic cerebellar syndrome). Confirming a therapeutic response to nicotinamide administration also has diagnostic significance.
Histidinemia: most current expert guidelines regard histidinemia as a benign metabolic abnormality that requires no treatment. Low-histidine dietary therapy was tried in the past, but long-term follow-up studies confirmed no difference in neurodevelopmental outcomes from untreated patients, so dietary restriction is no longer recommended. However, very rarely, symptoms such as seizures have been reported in histidinemia with extremely high blood histidine, and in such cases a low-histidine diet and pyridoxine (B6) supplementation may be tried.
Hartnup disease: the cornerstones of treatment are (1) nicotinamide (niacinamide) supplementation and (2) adequate dietary protein intake. Nicotinamide bypasses tryptophan-dependent niacin synthesis and directly corrects NAD+ deficiency. The recommended therapeutic dose in adults is nicotinamide 50–300 mg/day, and higher doses (up to 600 mg/day) are sometimes used in the symptomatic acute phase. With adequate dietary protein intake (1.5–2 g/kg/day), the absolute tryptophan supply can be partly preserved even though absorption efficiency is low. Blocking UV exposure, a trigger of symptom onset, is important, and routine sunscreen application, protective clothing, and adjusting the time spent outdoors are recommended. When triggers such as fever, diarrhea, or stress are present, the nicotinamide dose is temporarily increased. Fluid replacement and maintenance of electrolyte balance are also important. Topical steroids or moisturizers can be used for skin symptoms. In formiminoglutamic aciduria, folate supplementation (folinic acid or folic acid) is reported to partially correct the metabolic disorder caused by FTCD deficiency.
Histidinemia: the prognosis is very good. According to the current literature, individuals diagnosed with histidinemia show normal intellectual and physical development regardless of treatment and have normal life expectancy. The association with speech delay raised in early reports was not subsequently confirmed and was most likely the result of ascertainment bias. Therefore, the diagnosis of histidinemia itself has no important prognostic significance, and it is important to communicate this clearly to patients and families.
Hartnup disease: the prognosis is generally good when nicotinamide supplementation and adequate protein intake are maintained. Both skin rash and neurological symptoms respond well to nicotinamide administration, and marked symptom relief is expected within days to weeks after starting treatment. In terms of natural history, symptoms tend to lessen with age into adulthood, which is explained by the development of alternative amino acid absorption pathways through intestinal peptide transporters (PepT1, etc.) along with neural crest cell maturation. If left untreated, recurrent attacks of cerebellar ataxia, skin damage, and psychiatric symptoms can reduce quality of life. Life expectancy is close to normal, and chronic neurological disorders or organ damage are rare.
Primary prevention of disorders of aromatic amino acid metabolism is achieved through genetic counseling. Because both diseases are autosomal recessive, pregnancies between carrier parents carry a 25% risk of being affected. Parents of a confirmed affected child are offered the option of prenatal genetic testing (search for pathogenic HAL or SLC6A19 variants) or preimplantation genetic testing (PGT-M) in the next pregnancy.
Histidinemia: no preventive measures are needed. It is important for the attending physician to be familiar with current guidelines so as not to impose unnecessary dietary restrictions or treatment on the patient.
Hartnup disease: the following measures are recommended to prevent symptom onset in affected individuals. (1) Adequate protein intake (1.5–2 g/kg/day or more, actively eating foods high in tryptophan if needed). (2) Preventive nicotinamide supplementation (some experts recommend routine low-dose nicotinamide supplementation even during asymptomatic periods). (3) UV protection: daily sunscreen application (SPF 30 or higher) and protective clothing when outdoors. (4) Avoidance of triggers: prompt fluid and electrolyte replacement and increased nicotinamide dose during diarrhea and fever. (5) Regular follow-up: growth and development assessment in childhood, and follow-up plasma and urine amino acid testing. Education to obtain understanding and support from those around the patient when symptoms appear at school and in social life is also important.